Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts-Reference-Cited by-同舟云学术

Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts

Published:2018-08-02 Issue:12 Volume:97 Page:2309-2317
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Baek Dong Won,Lee Yoo Jin,Kim Hyunjeong,Ahn Seo Yeon,Ahn Jae Sook,Shin Ho Jin,Lee Won Sik,Lee Sang Min,Song Ik Chan,Lee Ho Sup,Park Sung Woo,Choi Yunsuk,Cho Yoon Young,Bae Sung Hwa,Kim Hyeoung Joon,Sohn Sang Kyun,Moon Joon Ho

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-018-3458-7/fulltext.html

Reference33 articles.

1. Tefferi A, Vardiman JW (2009) Myelodysplastic syndromes. N Engl J Med 361(19):1872–1885

2. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012) Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood 120(12):2454–2465

3. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079–2088

4. Mittelman M, Oster HS, Hoffman M, Neumann D (2010) The lower risk MDS patient at risk of rapid progression. Leuk Res 34(12):1551–1555

5. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O’Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P, National Comprehensive Cancer N (2011) NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. J Natl Compr Cancer Netw 9(1):30–56

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes;Seminars in Hematology;2024-08

2. Meta-analysis of the benefit of hypomethylating agents before allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes;Clinical and Experimental Medicine;2021-04-17

3. No clear survival benefit of azacitidine for lower‐risk myelodysplastic syndromes: A retrospective study of Nagasaki;Cancer Science;2020-10-23

4. Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?;Leukemia;2020-07-13

5. Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years;Expert Review of Anticancer Therapy;2020-06-01